Cost utility analysis of immunosuppressive regimens in adult renal transplant recipients in England and Wales

References

• LeveyASEckardtKUTsukamotoYDefinition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO)Kidney Int20056762089210015882252
   PubMed Web of Science ®Google Scholar
• EknoyanGChronic kidney disease definition and classification: no need for a rush to judgmentKidney Int200975101015101819262459
   PubMed Web of Science ®Google Scholar
• Abdel-KaderKUnruhMLWeisbodSDSymptom burden, depression, and quality of life in chronic and end-stage kidney diseaseClin J Am Soc Nephrol2009461057106419423570
   PubMed Web of Science ®Google Scholar
• National Institute for Clinical Excellence [homepage on the Internet]Immunosuppressive therapy for renal transplantation in adultsTechnical Appraisal 8592004 Available from: www.nice.org.uk/TA85Accessed March 3, 2014
   Google Scholar
• OpelzGDöhlerBCollaborative Transplant Study Report. Influence of time of rejection on long-term graft survival in renal transplantationTransplantation200885566166618337655
   PubMed Web of Science ®Google Scholar
• McEwanPDixonSBaboolalKConwayPCurrieCJEvaluation of the cost effectiveness of sirolimus versus tacrolimus for immunosuppression following renal transplantation in the UKPharmacoeconomics2006241677916445304
   PubMed Web of Science ®Google Scholar
• Organ Donation and TransplantationActivity Report 2012/13 Available from: http://www.organdonation.nhs.uk/statistics/transplant_activity_report/archive_activity_reports/pdf/ukt/activity_report_2012_13.pdfAccessed March 1, 2014
   Google Scholar
• UK Renal Registry [homepage on the Internet]UK Renal Registry 15th Annual Report: Chapter 5 Survival and Cause of Death of Adult Patients on Renal Replacement Therapy in 2011: national and centre-specific analyses Available from: http://www.renalreg.com/Reports/2012.htmlAccessed March 3, 2014
   Google Scholar
• National Institute for Health and Care Excellence [homepage on the Internet]The guidelines manual 2012112012 Available from: http://www.nice.org.uk/guidance/pmg6Accessed March 3, 2014
   Google Scholar
• WellsGASultanSAChenLKhanMCoyleDIndirect evidence: indirect treatment comparisons in meta-analysisOttawaCanadian Agency for Drugs and Technologies in Health2009 Available from: http://www.cadth.ca/en/products/health-technology-assessment/publication/884Accessed September 16, 2014
   Google Scholar
• WebsterACWoodroffeRCTaylorRSChapmanJRCraigJCTacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial dataBMJ2005331752081082016157605
   PubMed Web of Science ®Google Scholar
• WebsterACLeeVWChapmanJRCraigJCTarget of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trialsTransplantation20068191234124816699448
   PubMed Web of Science ®Google Scholar
• JürgensenJSArnsWHassBCost-effectiveness of immunosuppressive regimens in renal transplant recipients in Germany: a model approachEur J Health Econ2010111152519296139
   PubMed Web of Science ®Google Scholar
• LeeAJMorganCLConwayPCurrieCJCharacterisation and comparison of health-related quality of life for patients with renal failureCurr Med Res Opin200521111777178316307698
   PubMed Web of Science ®Google Scholar
• SilvaHTYangHCAbouljoudMOne-year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipientsAm J Transplant20077359560817217442
   PubMed Web of Science ®Google Scholar
• British National Formulary [homepage on the Internet]BNF 66BMJ Group2013 Available from: http://www.bnf.orgAccessed February 3, 2014
   Google Scholar
• KuypersDRPeetersPCSennesaelJJImproved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoringTransplantation201395233334023263559
   PubMed Web of Science ®Google Scholar
• MudumaGOdeyemiISmith-PalmerJPollockRFBudget impact of switching from an immediate-release to a prolonged-release formulation of tacrolimus in renal transplant recipients in the UK based on differences in adherencePatient Prefer Adherence2014839139924729687
   PubMed Web of Science ®Google Scholar
• ZhangJYuKFWhat’s the relative risk? A method of correcting the odds ratio in cohort studies of common outcomesJAMA199828019169016919832001
   PubMed Web of Science ®Google Scholar
• KramerBCharpentierBBackmanLTacrolimus once daily (ADVAGRAF) versus twice daily (PROGRAF) in de novo renal transplantation: a randomized phase III studyAm J Transplant201010122632264320840480
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence [homepage on the Internet]Peritoneal dialysis in the treatment of stage 5 chronic kidney diseaseNICE clinical guideline 12572011 Available from: http://www.nice.org.uk/guidance/cg125Accessed March 3, 2014
   Google Scholar
• Rate Inflation [homepage on the Internet]. Consumer price index Available from: http://www.rateinflation.comAccessed March 3, 2014
   Google Scholar
• National Institute for Health and Care Excellence [homepage on the Internet]Guide to the methods of technology appraisal42013 Available from: http://www.nice.org.uk/guidance/pmg9Accessed March 3, 2014
   Google Scholar
• Office of national statistics [homepage on the Internet]National Life tables, 2010–2012 available from: http://www.ons.gov.uk/ons/publications/re-reference-tables.html?edition=tcm%3A77-325699Accessed March 3, 2014
   Google Scholar
• All Wales Medicines Strategy Group [homepage on the Internet]AWMSG secretariat assessment report – Advice No. 1712 Belatacept (Nulojix^®▼) 250 mg powder for concentrate for solution for infusion52012 Available from: http://www.awmsg.org/awmsgonline/app/appraisalinfo/430Accessed August 14, 2014
   Google Scholar
• GamboaOMonteroCMesaLCost-effectiveness analysis of the early conversion of tacrolimus to mammalian target of rapamycin inhibitors in patients with renal transplantationTransplant Proc20114393367337622099798
   PubMed Web of Science ®Google Scholar
• RelyKGalindo-SuarezRAlexandrePCost utility of sirolimus versus tacrolimus for the primary prevention of graft rejection in renal transplant recipients in MexicoValue in Health Regional Issues20121211217
   Google Scholar
• EkbergHTedesco-SilvaHDemirbasAReduced exposure to calcineurin inhibitors in renal transplantationN Engl J Med2007357252562257518094377
   PubMed Web of Science ®Google Scholar
• EkbergHBernasconiCTedesco-SilvaHCalcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantationAm J Transplant2009981876188519563339
   PubMed Web of Science ®Google Scholar
• DaviesCBriggsALorgellyPGarellickGMalchauHThe “hazards” of extrapolating survival curvesMed Decis Making201333336938023457025
   PubMed Web of Science ®Google Scholar